Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7806 News 


«12...4567891011121314...156157»
  • ||||||||||  tibulizumab (ZB-106) / Zura Bio
    Enrollment closed:  A Study of LY3090106 in Participants With Sj (clinicaltrials.gov) -  Feb 20, 2018   
    P1,  N=32, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=60 --> 23 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Trial completion date:  SINAPPS-1: Study of Immunotherapy in Autoantibody Positive Psychosis (clinicaltrials.gov) -  Feb 19, 2018   
    P=N/A,  N=10, Completed, 
    Recruiting --> Completed | N=20 --> 10 | Trial primary completion date: Dec 2015 --> May 2017 Recruiting --> Completed | Trial completion date: Oct 2017 --> Dec 2017
  • ||||||||||  Trial completion:  Pre-POINT-Early Study (clinicaltrials.gov) -  Feb 13, 2018   
    P2,  N=44, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Feb 2018 | Trial primary completion date: Jan 2018 --> Feb 2018 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Open-label Study of Liothyronine in MS (clinicaltrials.gov) -  Feb 12, 2018   
    P1b,  N=20, Completed, 
    Recruiting --> Completed | Trial completion date: Mar 2018 --> Nov 2017 | Trial primary completion date: Sep 2017 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Sep 2017
  • ||||||||||  Catena (idebenone) / Chiesi
    Trial primary completion date:  Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) -  Feb 9, 2018   
    P1/2,  N=85, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2017 --> Sep 2017 | Trial primary completion date: Aug 2017 --> Sep 2017 Trial primary completion date: Aug 2018 --> Apr 2018
  • ||||||||||  Orencia (abatacept) / BMS
    Trial completion, Enrollment change:  ReACTION: Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting (clinicaltrials.gov) -  Feb 7, 2018   
    P=N/A,  N=153, Completed, 
    Completed --> Terminated; Study was terminated by sponsor due to market authorization of tocilizumab for the study population. Active, not recruiting --> Completed | N=220 --> 153
  • ||||||||||  Trial completion date, Trial primary completion date:  The Clinical Efficacy of DFPP in Patients With AAGN (clinicaltrials.gov) -  Feb 6, 2018   
    P=N/A,  N=14, Terminated, 
    Enrolling by invitation --> Completed | Trial primary completion date: Jun 2017 --> Feb 2017 Trial primary completion date: Nov 2017 --> Apr 2017 | Trial completion date: Nov 2018 --> Apr 2017
  • ||||||||||  Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM) (clinicaltrials.gov) -  Feb 5, 2018   
    P=N/A,  N=211, Completed, 
    Trial primary completion date: Nov 2017 --> Apr 2017 | Trial completion date: Nov 2018 --> Apr 2017 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=272 --> 211 | Trial primary completion date: Jun 2013 --> Jul 2015
  • ||||||||||  daxdilimab (HZN-7734) / Horizon Therapeutics
    Trial completion, Trial completion date:  A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases (clinicaltrials.gov) -  Feb 5, 2018   
    P1,  N=36, Completed, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A | N=272 --> 211 | Trial primary completion date: Jun 2013 --> Jul 2015 Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Nov 2017
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Trial termination, Trial primary completion date:  RITUXILUP: Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis (clinicaltrials.gov) -  Feb 1, 2018   
    P3,  N=24, Terminated, 
    Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Dec 2017; Study assessments for patients recruited continuing per protocol so patients receive a minimum of 6 months follow up. No safety concerns have been raised.
  • ||||||||||  Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
    Trial completion:  Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) -  Feb 1, 2018   
    P2,  N=71, Completed, 
    No safety concerns have been raised. Active, not recruiting --> Completed
  • ||||||||||  HDV insulin lispro (HDV-L) / Diasome
    Trial primary completion date, Combination therapy:  Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1) (clinicaltrials.gov) -  Feb 1, 2018   
    P2b,  N=157, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> Feb 2018
  • ||||||||||  Catena (idebenone) / Chiesi
    Trial primary completion date:  Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) -  Jan 31, 2018   
    P1/2,  N=85, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Oct 2017 Trial primary completion date: Jan 2018 --> Aug 2018
  • ||||||||||  thyroxine / Generic mfg.
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Selenium Supplementation in Pregnancy (clinicaltrials.gov) -  Jan 30, 2018   
    P=N/A,  N=56, Completed, 
    N=45 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) -  Jan 30, 2018   
    P3,  N=121, Terminated, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A | N=150 --> 56 | Trial primary completion date: May 2015 --> Jun 2017 N=536 --> 121 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jan 2018; Unbalance in the composite endpoint between arms.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Enrollment change, Trial termination, Trial primary completion date:  Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) (clinicaltrials.gov) -  Jan 29, 2018   
    P1b,  N=12, Terminated, 
    N=536 --> 121 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jan 2018; Unbalance in the composite endpoint between arms. N=40 --> 12 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Jan 2018; Insufficient enrollment, no safety or efficacy concerns
  • ||||||||||  Myasterix (CV-MG01) / CuraVac
    Trial primary completion date, IO biomarker:  Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis (clinicaltrials.gov) -  Jan 29, 2018   
    P1/2,  N=24, Active, not recruiting, 
    N=40 --> 12 | Recruiting --> Terminated | Trial primary completion date: Jun 2018 --> Jan 2018; Insufficient enrollment, no safety or efficacy concerns Trial primary completion date: Sep 2017 --> Sep 2019
  • ||||||||||  Enrollment closed, Trial primary completion date:  Psychosocial Functioning in Young Adults With Type 1 Diabetes (clinicaltrials.gov) -  Jan 29, 2018   
    P=N/A,  N=120, Active, not recruiting, 
    Trial primary completion date: Sep 2017 --> Sep 2019 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2018
  • ||||||||||  Trial initiation date:  Tissue Sodium in Autoimmune Disease (clinicaltrials.gov) -  Jan 25, 2018   
    P=N/A,  N=21, Not yet recruiting, 
    Recruiting --> Completed | N=158 --> 124 Initiation date: Dec 2017 --> Dec 2018
  • ||||||||||  Sylvant (siltuximab) / Jazz
    Trial completion:  Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes (clinicaltrials.gov) -  Jan 18, 2018   
    P1,  N=10, Completed, 
    Active, not recruiting --> Completed | N=15 --> 19 | Trial primary completion date: Jan 2018 --> Mar 2017 Active, not recruiting --> Completed
  • ||||||||||  gerilimzumab (ARGX-109) / argenx
    Trial initiation date, Trial primary completion date:  Study Evaluating Gerilimzumab (clinicaltrials.gov) -  Jan 18, 2018   
    P2,  N=200, Not yet recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Initiation date: Nov 2016 --> Jan 2018 | Trial primary completion date: May 2018 --> May 2019
  • ||||||||||  Trial completion, Enrollment change, IO biomarker:  Immune Profile in Subjects With New Onset Type 1 Diabetes (clinicaltrials.gov) -  Jan 18, 2018   
    P=N/A,  N=22, Completed, 
    Recruiting --> Completed | N=60 --> 74 Recruiting --> Completed | N=30 --> 22